The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Mosunetuzumab + zanubrutinib for newly diagnosed high-burden FL: first results of MITHIC-FL2
Lorenzo Falchi, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the preliminary results of the multicenter Phase II MITHIC-FL2 trial (NCT05389293), which is investigating mosunetuzumab plus zanubrutinib for the treatment of newly diagnosed high-burden follicular lymphoma (FL). Although follow-up is still short, Dr Falchi highlights that early results appear promising. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
